🇺🇸 FDA
Drug

rituximab

Brand: RITUXAN

approved

Quick answer

rituximab (RITUXAN), is a pharmaceutical active ingredient, with approved status in the US.

Key facts

INN
rituximab
Brand
RITUXAN
Route
SUBCUTANEOUS
Formulation
SOLUTION

Related patents

patent

US 11896617

Polynucleotides encoding rituximab-resistant chimeric antigen receptors

Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

Related news

Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
NewsMetabolic disorders and oncologyMay 1, 2026

Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results

Eli Lilly announces FDA approval of Foundayo (orforglipron) for obesity treatment alongside positive Phase 3 results and raised full-year guidance in Q1 2026.

Daniel Brooks

Frequently asked questions

What is rituximab?

rituximab (RITUXAN), is a pharmaceutical active ingredient, with approved status in the US.

What is the brand name for rituximab?

RITUXAN is a marketed brand name for rituximab. Check FDA Drugs@FDA for the current US label holder.